NCT03485547 2026-02-02Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Dana-Farber Cancer InstitutePhase 1 Completed5 enrolled